| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 313 | 2024 | 10856 | 10.580 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 128 | 2024 | 1517 | 8.280 |
Why?
|
| Tetrazoles | 123 | 2024 | 835 | 7.380 |
Why?
|
| Myocardial Infarction | 248 | 2024 | 11690 | 7.130 |
Why?
|
| Stroke Volume | 195 | 2024 | 4983 | 6.330 |
Why?
|
| Spironolactone | 44 | 2024 | 382 | 5.330 |
Why?
|
| Ventricular Dysfunction, Left | 103 | 2024 | 2059 | 5.330 |
Why?
|
| Biphenyl Compounds | 96 | 2024 | 914 | 4.950 |
Why?
|
| Captopril | 60 | 2015 | 272 | 4.810 |
Why?
|
| Antihypertensive Agents | 57 | 2023 | 2043 | 4.430 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 64 | 2020 | 453 | 4.390 |
Why?
|
| Angiotensin Receptor Antagonists | 59 | 2024 | 923 | 3.790 |
Why?
|
| Hematinics | 22 | 2018 | 281 | 3.620 |
Why?
|
| Cardiovascular Diseases | 134 | 2023 | 15108 | 3.580 |
Why?
|
| Ventricular Function, Left | 88 | 2023 | 3656 | 3.350 |
Why?
|
| Benzimidazoles | 54 | 2020 | 848 | 3.240 |
Why?
|
| Anemia | 27 | 2021 | 1499 | 3.170 |
Why?
|
| Ventricular Remodeling | 34 | 2019 | 1224 | 3.140 |
Why?
|
| Valine | 31 | 2014 | 413 | 3.090 |
Why?
|
| Ramipril | 18 | 2024 | 95 | 2.960 |
Why?
|
| Diabetes Mellitus, Type 2 | 47 | 2023 | 11695 | 2.910 |
Why?
|
| Renin-Angiotensin System | 28 | 2020 | 759 | 2.750 |
Why?
|
| Natriuretic Peptide, Brain | 22 | 2023 | 1573 | 2.520 |
Why?
|
| Renal Insufficiency, Chronic | 27 | 2022 | 2195 | 2.440 |
Why?
|
| Acute Coronary Syndrome | 16 | 2023 | 2337 | 2.350 |
Why?
|
| Kidney Failure, Chronic | 27 | 2023 | 2536 | 2.260 |
Why?
|
| Amides | 15 | 2022 | 458 | 2.220 |
Why?
|
| Hypertrophy, Left Ventricular | 29 | 2022 | 859 | 2.160 |
Why?
|
| Fumarates | 11 | 2020 | 132 | 2.150 |
Why?
|
| Randomized Controlled Trials as Topic | 93 | 2023 | 9941 | 2.050 |
Why?
|
| Kidney Diseases | 29 | 2021 | 2145 | 1.950 |
Why?
|
| Erythropoietin | 14 | 2015 | 724 | 1.950 |
Why?
|
| Hypertension | 77 | 2022 | 8455 | 1.870 |
Why?
|
| Double-Blind Method | 124 | 2022 | 12017 | 1.810 |
Why?
|
| Neprilysin | 16 | 2024 | 439 | 1.800 |
Why?
|
| Blood Pressure | 85 | 2021 | 8541 | 1.740 |
Why?
|
| Cardiomegaly | 40 | 2006 | 619 | 1.690 |
Why?
|
| Heart Ventricles | 48 | 2017 | 3801 | 1.520 |
Why?
|
| Peptide Fragments | 20 | 2023 | 5095 | 1.440 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 25 | 2023 | 3239 | 1.400 |
Why?
|
| Death, Sudden, Cardiac | 22 | 2021 | 1541 | 1.400 |
Why?
|
| Humans | 638 | 2024 | 742088 | 1.350 |
Why?
|
| Pravastatin | 26 | 2011 | 395 | 1.320 |
Why?
|
| Aged | 323 | 2023 | 162944 | 1.290 |
Why?
|
| Adrenergic beta-Antagonists | 21 | 2018 | 1239 | 1.270 |
Why?
|
| Drug Combinations | 28 | 2023 | 1961 | 1.230 |
Why?
|
| Myocardial Contraction | 26 | 2014 | 1585 | 1.230 |
Why?
|
| Pulmonary Edema | 4 | 2024 | 415 | 1.220 |
Why?
|
| Diabetic Angiopathies | 9 | 2019 | 820 | 1.210 |
Why?
|
| Cardiovascular Agents | 11 | 2019 | 848 | 1.210 |
Why?
|
| Prognosis | 132 | 2024 | 29010 | 1.210 |
Why?
|
| Clinical Trials as Topic | 38 | 2019 | 7901 | 1.200 |
Why?
|
| Hypoglycemic Agents | 12 | 2023 | 2866 | 1.180 |
Why?
|
| Middle Aged | 345 | 2023 | 213127 | 1.160 |
Why?
|
| Male | 441 | 2023 | 349538 | 1.160 |
Why?
|
| Proportional Hazards Models | 76 | 2022 | 12344 | 1.150 |
Why?
|
| Stroke | 41 | 2023 | 9963 | 1.140 |
Why?
|
| Glomerular Filtration Rate | 40 | 2022 | 2167 | 1.140 |
Why?
|
| Albuminuria | 10 | 2018 | 683 | 1.130 |
Why?
|
| Aspirin | 21 | 2021 | 3278 | 1.120 |
Why?
|
| Hospitalization | 75 | 2024 | 10232 | 1.110 |
Why?
|
| Kidney Transplantation | 16 | 2023 | 4246 | 1.090 |
Why?
|
| Female | 433 | 2023 | 379592 | 1.090 |
Why?
|
| Diabetes Complications | 14 | 2020 | 1359 | 1.070 |
Why?
|
| Peptides | 8 | 2023 | 4392 | 1.070 |
Why?
|
| Diabetic Nephropathies | 11 | 2019 | 983 | 1.050 |
Why?
|
| Risk Assessment | 65 | 2022 | 23320 | 1.050 |
Why?
|
| Risk Factors | 151 | 2023 | 72145 | 1.050 |
Why?
|
| Research Design | 23 | 2022 | 5979 | 0.930 |
Why?
|
| Renin | 7 | 2016 | 642 | 0.920 |
Why?
|
| Hyperkalemia | 9 | 2023 | 218 | 0.900 |
Why?
|
| Treatment Outcome | 142 | 2024 | 62966 | 0.900 |
Why?
|
| Renal Dialysis | 5 | 2019 | 1780 | 0.870 |
Why?
|
| Anticholesteremic Agents | 20 | 2022 | 979 | 0.860 |
Why?
|
| Peptidyl-Dipeptidase A | 10 | 2020 | 365 | 0.850 |
Why?
|
| Primary Prevention | 7 | 2020 | 1166 | 0.840 |
Why?
|
| Coronary Artery Disease | 15 | 2022 | 6454 | 0.820 |
Why?
|
| Cause of Death | 35 | 2021 | 3571 | 0.820 |
Why?
|
| Cardiac Output, Low | 11 | 2007 | 193 | 0.810 |
Why?
|
| Receptors, Angiotensin | 6 | 2024 | 142 | 0.790 |
Why?
|
| Echocardiography | 36 | 2022 | 5097 | 0.760 |
Why?
|
| Myocardium | 23 | 2019 | 4775 | 0.760 |
Why?
|
| Hemodynamics | 41 | 2014 | 4197 | 0.750 |
Why?
|
| Troponin T | 5 | 2021 | 749 | 0.710 |
Why?
|
| Heart Failure, Systolic | 6 | 2021 | 124 | 0.710 |
Why?
|
| Endpoint Determination | 9 | 2019 | 600 | 0.710 |
Why?
|
| Fatty Acid Desaturases | 1 | 2019 | 102 | 0.690 |
Why?
|
| Survival Rate | 49 | 2021 | 12773 | 0.680 |
Why?
|
| Systole | 25 | 2020 | 956 | 0.660 |
Why?
|
| Enalapril | 8 | 2022 | 327 | 0.660 |
Why?
|
| Angiotensins | 8 | 2024 | 151 | 0.640 |
Why?
|
| Clinical Trials Data Monitoring Committees | 4 | 2023 | 25 | 0.640 |
Why?
|
| Natriuretic Peptides | 5 | 2023 | 150 | 0.640 |
Why?
|
| Coronary Disease | 27 | 2011 | 6078 | 0.630 |
Why?
|
| Troponin I | 3 | 2018 | 619 | 0.630 |
Why?
|
| Cardiology | 4 | 2016 | 1658 | 0.620 |
Why?
|
| Follow-Up Studies | 96 | 2021 | 39004 | 0.610 |
Why?
|
| Calcium Channel Blockers | 8 | 2013 | 689 | 0.610 |
Why?
|
| Diabetes Mellitus | 22 | 2022 | 5724 | 0.600 |
Why?
|
| Ventricular Dysfunction, Right | 5 | 2023 | 578 | 0.590 |
Why?
|
| Drug Therapy, Combination | 35 | 2017 | 6483 | 0.580 |
Why?
|
| Aorta | 13 | 2007 | 2057 | 0.580 |
Why?
|
| Vasodilator Agents | 8 | 2022 | 976 | 0.580 |
Why?
|
| Creatinine | 18 | 2019 | 1916 | 0.580 |
Why?
|
| Defibrillators, Implantable | 12 | 2020 | 1440 | 0.570 |
Why?
|
| Kidney | 23 | 2023 | 7167 | 0.570 |
Why?
|
| Atrial Fibrillation | 19 | 2023 | 5019 | 0.560 |
Why?
|
| Sulfhydryl Compounds | 4 | 2022 | 296 | 0.530 |
Why?
|
| Kaplan-Meier Estimate | 26 | 2019 | 6534 | 0.530 |
Why?
|
| Pulsatile Flow | 7 | 2007 | 332 | 0.520 |
Why?
|
| Prospective Studies | 56 | 2024 | 53187 | 0.510 |
Why?
|
| Tissue Survival | 2 | 2014 | 118 | 0.510 |
Why?
|
| Platelet Aggregation Inhibitors | 12 | 2020 | 3067 | 0.510 |
Why?
|
| Diabetic Neuropathies | 1 | 2018 | 410 | 0.510 |
Why?
|
| Myocardial Revascularization | 8 | 2015 | 841 | 0.510 |
Why?
|
| Cardiac Resynchronization Therapy | 8 | 2014 | 532 | 0.500 |
Why?
|
| Risk Reduction Behavior | 5 | 2019 | 1123 | 0.500 |
Why?
|
| C-Reactive Protein | 14 | 2024 | 3766 | 0.500 |
Why?
|
| Amlodipine | 3 | 2014 | 83 | 0.490 |
Why?
|
| Cholesterol, LDL | 13 | 2018 | 2354 | 0.490 |
Why?
|
| Time Factors | 60 | 2021 | 40054 | 0.490 |
Why?
|
| Diuretics | 11 | 2022 | 591 | 0.490 |
Why?
|
| Indoles | 13 | 2019 | 1834 | 0.480 |
Why?
|
| Rats, Inbred SHR | 10 | 2018 | 195 | 0.480 |
Why?
|
| Predictive Value of Tests | 31 | 2022 | 15056 | 0.480 |
Why?
|
| Atrial Natriuretic Factor | 7 | 2011 | 393 | 0.450 |
Why?
|
| Bundle-Branch Block | 4 | 2014 | 270 | 0.440 |
Why?
|
| Diastole | 10 | 2018 | 791 | 0.440 |
Why?
|
| Heart | 21 | 2019 | 4462 | 0.440 |
Why?
|
| Survival Analysis | 41 | 2022 | 10248 | 0.440 |
Why?
|
| Esters | 4 | 2022 | 210 | 0.420 |
Why?
|
| Arrhythmias, Cardiac | 5 | 2018 | 2267 | 0.420 |
Why?
|
| Aldosterone | 4 | 2022 | 876 | 0.420 |
Why?
|
| Comorbidity | 34 | 2023 | 10372 | 0.410 |
Why?
|
| Data Interpretation, Statistical | 11 | 2018 | 2714 | 0.410 |
Why?
|
| Metformin | 1 | 2019 | 829 | 0.410 |
Why?
|
| Propanolamines | 5 | 2018 | 167 | 0.410 |
Why?
|
| Hypotension | 7 | 2023 | 880 | 0.400 |
Why?
|
| Angina, Unstable | 7 | 2015 | 926 | 0.390 |
Why?
|
| Vascular Diseases | 3 | 2018 | 1155 | 0.380 |
Why?
|
| Internationality | 4 | 2015 | 1002 | 0.380 |
Why?
|
| Pineal Gland | 4 | 1999 | 165 | 0.380 |
Why?
|
| Multivariate Analysis | 34 | 2017 | 12242 | 0.380 |
Why?
|
| Ticlopidine | 7 | 2015 | 899 | 0.380 |
Why?
|
| Electrocardiography | 26 | 2020 | 6440 | 0.380 |
Why?
|
| Aged, 80 and over | 57 | 2023 | 57683 | 0.380 |
Why?
|
| Evidence-Based Medicine | 6 | 2020 | 3611 | 0.370 |
Why?
|
| Cardiac Pacing, Artificial | 6 | 2019 | 846 | 0.370 |
Why?
|
| Hemoglobins | 7 | 2017 | 1532 | 0.370 |
Why?
|
| Atherosclerosis | 7 | 2023 | 3428 | 0.360 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2019 | 1341 | 0.360 |
Why?
|
| Supreme Court Decisions | 1 | 2011 | 128 | 0.360 |
Why?
|
| Cardiomyopathies | 4 | 2011 | 1912 | 0.350 |
Why?
|
| Chronic Disease | 28 | 2014 | 9144 | 0.350 |
Why?
|
| Europe | 11 | 2023 | 3339 | 0.350 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 2014 | 1107 | 0.350 |
Why?
|
| Diabetic Retinopathy | 1 | 2018 | 1205 | 0.350 |
Why?
|
| Cholesterol | 14 | 2021 | 2895 | 0.350 |
Why?
|
| Education, Medical, Continuing | 1 | 2015 | 839 | 0.340 |
Why?
|
| Legislation, Drug | 1 | 2011 | 206 | 0.340 |
Why?
|
| Potassium | 6 | 2022 | 1336 | 0.340 |
Why?
|
| Angiotensin II | 13 | 2004 | 881 | 0.330 |
Why?
|
| Thiazepines | 3 | 2005 | 30 | 0.330 |
Why?
|
| Recurrence | 33 | 2018 | 8333 | 0.330 |
Why?
|
| Recovery of Function | 4 | 2019 | 2924 | 0.320 |
Why?
|
| Diabetes Mellitus, Type 1 | 3 | 2018 | 3336 | 0.320 |
Why?
|
| Rats | 77 | 2018 | 24265 | 0.310 |
Why?
|
| Heart Rupture, Post-Infarction | 2 | 2010 | 49 | 0.310 |
Why?
|
| Patients | 1 | 2014 | 892 | 0.310 |
Why?
|
| Mitral Valve Insufficiency | 5 | 2012 | 1415 | 0.310 |
Why?
|
| Cicatrix | 2 | 2013 | 761 | 0.310 |
Why?
|
| Cardiac Output | 28 | 2005 | 853 | 0.310 |
Why?
|
| History, 21st Century | 3 | 2019 | 1533 | 0.310 |
Why?
|
| Practice Guidelines as Topic | 10 | 2020 | 7276 | 0.310 |
Why?
|
| Quality of Life | 19 | 2021 | 12730 | 0.310 |
Why?
|
| Thrombolytic Therapy | 4 | 2013 | 2161 | 0.310 |
Why?
|
| Heart Arrest | 9 | 2022 | 1469 | 0.310 |
Why?
|
| Aortic Valve Stenosis | 1 | 2020 | 1941 | 0.300 |
Why?
|
| Pulse | 3 | 2002 | 229 | 0.300 |
Why?
|
| Angina Pectoris | 6 | 2015 | 977 | 0.290 |
Why?
|
| Russia | 6 | 2018 | 409 | 0.280 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2013 | 851 | 0.280 |
Why?
|
| Folic Acid | 6 | 2017 | 1300 | 0.280 |
Why?
|
| Alphavirus Infections | 1 | 2006 | 17 | 0.280 |
Why?
|
| Incidence | 30 | 2022 | 20928 | 0.280 |
Why?
|
| Renal Insufficiency | 6 | 2016 | 802 | 0.280 |
Why?
|
| Cholesterol, HDL | 8 | 2015 | 1813 | 0.280 |
Why?
|
| History, 20th Century | 3 | 2019 | 2739 | 0.270 |
Why?
|
| Chikungunya virus | 1 | 2006 | 50 | 0.270 |
Why?
|
| Vitamin B Complex | 3 | 2016 | 288 | 0.270 |
Why?
|
| Patient Selection | 7 | 2020 | 4214 | 0.270 |
Why?
|
| Norepinephrine | 10 | 2003 | 909 | 0.270 |
Why?
|
| Echocardiography, Doppler | 4 | 2014 | 934 | 0.270 |
Why?
|
| Fibrinolysis | 2 | 1997 | 322 | 0.260 |
Why?
|
| Sex Factors | 17 | 2021 | 10392 | 0.260 |
Why?
|
| Morbidity | 12 | 2020 | 1767 | 0.260 |
Why?
|
| Heart-Assist Devices | 2 | 2014 | 1194 | 0.260 |
Why?
|
| Heart Rate | 25 | 2017 | 4091 | 0.250 |
Why?
|
| Drug Industry | 1 | 2011 | 744 | 0.250 |
Why?
|
| Losartan | 2 | 2003 | 298 | 0.250 |
Why?
|
| Mortality | 10 | 2019 | 2857 | 0.250 |
Why?
|
| Hypolipidemic Agents | 5 | 2009 | 604 | 0.250 |
Why?
|
| Prediabetic State | 2 | 2022 | 493 | 0.250 |
Why?
|
| Models, Cardiovascular | 3 | 2006 | 994 | 0.250 |
Why?
|
| Canada | 12 | 2017 | 2061 | 0.240 |
Why?
|
| Georgia (Republic) | 4 | 2018 | 41 | 0.240 |
Why?
|
| Hypertension, Renal | 1 | 2004 | 177 | 0.240 |
Why?
|
| Prescription Drugs | 1 | 2011 | 595 | 0.240 |
Why?
|
| Hyperhomocysteinemia | 2 | 2017 | 124 | 0.240 |
Why?
|
| Rats, Wistar | 17 | 2001 | 1902 | 0.240 |
Why?
|
| Disease Progression | 18 | 2019 | 13256 | 0.240 |
Why?
|
| Secondary Prevention | 6 | 2019 | 1520 | 0.230 |
Why?
|
| Stem Cell Transplantation | 1 | 2012 | 1618 | 0.230 |
Why?
|
| Cardiovascular Physiological Phenomena | 4 | 2006 | 235 | 0.230 |
Why?
|
| Postoperative Complications | 6 | 2018 | 15244 | 0.230 |
Why?
|
| Dose-Response Relationship, Drug | 18 | 2020 | 10943 | 0.230 |
Why?
|
| Adult | 85 | 2020 | 213712 | 0.230 |
Why?
|
| Europe, Eastern | 1 | 2023 | 75 | 0.230 |
Why?
|
| Kidney Function Tests | 10 | 2019 | 683 | 0.230 |
Why?
|
| Cohort Studies | 29 | 2022 | 40450 | 0.230 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 5 | 2016 | 2276 | 0.230 |
Why?
|
| Severity of Illness Index | 25 | 2021 | 15530 | 0.220 |
Why?
|
| Erythrocyte Indices | 1 | 2023 | 146 | 0.220 |
Why?
|
| Rats, Inbred Strains | 30 | 1996 | 2191 | 0.220 |
Why?
|
| Pharmacogenetics | 4 | 2022 | 676 | 0.220 |
Why?
|
| Polymorphism, Genetic | 7 | 2020 | 4328 | 0.220 |
Why?
|
| Sphygmomanometers | 2 | 1999 | 15 | 0.210 |
Why?
|
| Registries | 8 | 2020 | 8077 | 0.210 |
Why?
|
| Hypokalemia | 3 | 2019 | 153 | 0.210 |
Why?
|
| Arylamine N-Acetyltransferase | 3 | 1999 | 86 | 0.210 |
Why?
|
| Exercise Therapy | 3 | 2020 | 904 | 0.210 |
Why?
|
| Protease Inhibitors | 2 | 2005 | 790 | 0.210 |
Why?
|
| Ventricular Premature Complexes | 1 | 2003 | 111 | 0.210 |
Why?
|
| Animals | 105 | 2019 | 168561 | 0.210 |
Why?
|
| Multicenter Studies as Topic | 11 | 2010 | 1661 | 0.200 |
Why?
|
| Elasticity | 7 | 2007 | 657 | 0.200 |
Why?
|
| Atrial Function, Left | 2 | 2021 | 173 | 0.200 |
Why?
|
| United States | 44 | 2023 | 69693 | 0.200 |
Why?
|
| Pulmonary Circulation | 2 | 2024 | 739 | 0.200 |
Why?
|
| Isoproterenol | 4 | 1999 | 399 | 0.200 |
Why?
|
| Tachycardia, Ventricular | 4 | 2011 | 1272 | 0.200 |
Why?
|
| Population Surveillance | 2 | 2016 | 2616 | 0.200 |
Why?
|
| North America | 6 | 2017 | 1249 | 0.190 |
Why?
|
| Proteinuria | 4 | 2009 | 657 | 0.190 |
Why?
|
| Catecholamines | 1 | 2001 | 387 | 0.190 |
Why?
|
| Myocardial Reperfusion | 2 | 2005 | 351 | 0.190 |
Why?
|
| Fibroblast Growth Factors | 2 | 2019 | 879 | 0.190 |
Why?
|
| Ventricular Pressure | 1 | 2021 | 199 | 0.190 |
Why?
|
| Arteries | 3 | 2005 | 1118 | 0.190 |
Why?
|
| Hypercholesterolemia | 4 | 2010 | 1149 | 0.190 |
Why?
|
| Ultrasonography | 15 | 2014 | 5978 | 0.180 |
Why?
|
| Cardiac Volume | 10 | 2012 | 210 | 0.180 |
Why?
|
| Up-Regulation | 4 | 2017 | 4211 | 0.180 |
Why?
|
| Buspirone | 3 | 1994 | 82 | 0.180 |
Why?
|
| Travel | 1 | 2006 | 788 | 0.180 |
Why?
|
| Risk | 17 | 2020 | 9679 | 0.180 |
Why?
|
| Data Collection | 4 | 2018 | 3339 | 0.180 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2020 | 137 | 0.170 |
Why?
|
| Sympatholytics | 3 | 2004 | 83 | 0.170 |
Why?
|
| Carbazoles | 2 | 2003 | 226 | 0.170 |
Why?
|
| Age Factors | 22 | 2021 | 18355 | 0.170 |
Why?
|
| Gated Blood-Pool Imaging | 1 | 1999 | 44 | 0.170 |
Why?
|
| Anticoagulants | 9 | 2023 | 4595 | 0.170 |
Why?
|
| Biomedical Research | 1 | 2015 | 3306 | 0.170 |
Why?
|
| Placebos | 12 | 2015 | 1677 | 0.170 |
Why?
|
| South America | 3 | 2016 | 181 | 0.170 |
Why?
|
| Polypharmacy | 1 | 2021 | 294 | 0.170 |
Why?
|
| Disease Outbreaks | 3 | 2006 | 1768 | 0.170 |
Why?
|
| Hemorrhage | 4 | 2009 | 3461 | 0.160 |
Why?
|
| Heptanoic Acids | 3 | 2005 | 343 | 0.160 |
Why?
|
| Pyrrolidines | 1 | 2000 | 342 | 0.160 |
Why?
|
| Linoleic Acid | 1 | 2019 | 157 | 0.160 |
Why?
|
| Insulin | 5 | 2018 | 6575 | 0.160 |
Why?
|
| Circadian Rhythm | 3 | 1999 | 2623 | 0.160 |
Why?
|
| Treatment Failure | 5 | 2015 | 2615 | 0.160 |
Why?
|
| Arachidonic Acid | 1 | 2019 | 434 | 0.160 |
Why?
|
| Research | 2 | 2006 | 1999 | 0.160 |
Why?
|
| Ventricular Function, Right | 4 | 2023 | 592 | 0.160 |
Why?
|
| Pyridines | 4 | 2016 | 2818 | 0.160 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 3130 | 0.160 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 3236 | 0.150 |
Why?
|
| Demography | 3 | 2013 | 1650 | 0.150 |
Why?
|
| Canrenone | 1 | 2017 | 4 | 0.150 |
Why?
|
| Respiratory Mucosa | 2 | 2012 | 427 | 0.150 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 1998 | 246 | 0.150 |
Why?
|
| Death, Sudden | 2 | 2018 | 298 | 0.150 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 4 | 2021 | 3038 | 0.150 |
Why?
|
| Models, Statistical | 7 | 2018 | 5100 | 0.150 |
Why?
|
| Glucuronidase | 1 | 2019 | 207 | 0.150 |
Why?
|
| Drug Administration Schedule | 9 | 2015 | 4929 | 0.150 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2001 | 849 | 0.150 |
Why?
|
| Vascular Resistance | 11 | 1999 | 936 | 0.150 |
Why?
|
| Hyperphosphatemia | 1 | 2017 | 40 | 0.150 |
Why?
|
| Heart Failure, Diastolic | 1 | 2018 | 69 | 0.150 |
Why?
|
| United States Food and Drug Administration | 5 | 2020 | 1581 | 0.150 |
Why?
|
| Pulmonary Gas Exchange | 1 | 1998 | 381 | 0.140 |
Why?
|
| Therapeutic Human Experimentation | 1 | 2016 | 42 | 0.140 |
Why?
|
| Influenza Vaccines | 3 | 2022 | 733 | 0.140 |
Why?
|
| Pulmonary Ventilation | 1 | 1998 | 372 | 0.140 |
Why?
|
| Judgment | 1 | 2018 | 281 | 0.140 |
Why?
|
| Heart Atria | 4 | 2014 | 1348 | 0.140 |
Why?
|
| Cerebrovascular Disorders | 3 | 1999 | 1499 | 0.140 |
Why?
|
| Pacemaker, Artificial | 3 | 2019 | 817 | 0.140 |
Why?
|
| Case-Control Studies | 8 | 2018 | 21719 | 0.140 |
Why?
|
| Neurotransmitter Agents | 3 | 2002 | 647 | 0.140 |
Why?
|
| RNA, Messenger | 7 | 1999 | 13029 | 0.140 |
Why?
|
| Blood Volume | 7 | 2010 | 565 | 0.140 |
Why?
|
| Phosphorus | 1 | 2017 | 338 | 0.140 |
Why?
|
| Nifedipine | 1 | 1996 | 226 | 0.140 |
Why?
|
| Nephritis, Interstitial | 1 | 2017 | 156 | 0.130 |
Why?
|
| Diffusion of Innovation | 2 | 2016 | 725 | 0.130 |
Why?
|
| Sulfonamides | 3 | 2014 | 1932 | 0.130 |
Why?
|
| Genotype | 10 | 2021 | 12946 | 0.130 |
Why?
|
| Encephalitis Virus, Venezuelan Equine | 3 | 1999 | 5 | 0.130 |
Why?
|
| Statistics as Topic | 4 | 2018 | 2372 | 0.130 |
Why?
|
| Extracellular Matrix | 2 | 2020 | 1740 | 0.130 |
Why?
|
| Medication Adherence | 4 | 2017 | 2055 | 0.130 |
Why?
|
| Aging | 9 | 2016 | 8626 | 0.130 |
Why?
|
| Vascular Patency | 2 | 1995 | 885 | 0.130 |
Why?
|
| Lipids | 4 | 2010 | 3302 | 0.130 |
Why?
|
| Myocardial Ischemia | 6 | 2019 | 2145 | 0.130 |
Why?
|
| Lung Diseases | 2 | 2019 | 1884 | 0.130 |
Why?
|
| Hypoglycemia | 1 | 2022 | 859 | 0.130 |
Why?
|
| Coronary Vessels | 8 | 2006 | 3099 | 0.130 |
Why?
|
| Pneumonia | 2 | 2021 | 2117 | 0.120 |
Why?
|
| Uric Acid | 1 | 2020 | 760 | 0.120 |
Why?
|
| Internship and Residency | 1 | 2015 | 5774 | 0.120 |
Why?
|
| Hyperuricemia | 1 | 2017 | 208 | 0.120 |
Why?
|
| Heart Function Tests | 3 | 2004 | 330 | 0.120 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2018 | 839 | 0.120 |
Why?
|
| Exercise Tolerance | 2 | 2015 | 770 | 0.120 |
Why?
|
| Thrombosis | 3 | 1997 | 2966 | 0.120 |
Why?
|
| Carbon Dioxide | 1 | 1998 | 1141 | 0.120 |
Why?
|
| Pandemics | 4 | 2022 | 8328 | 0.120 |
Why?
|
| Pyrroles | 3 | 2005 | 1143 | 0.120 |
Why?
|
| Smoking | 7 | 2021 | 8969 | 0.120 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 1994 | 110 | 0.120 |
Why?
|
| Heart Diseases | 4 | 1998 | 2789 | 0.120 |
Why?
|
| Analysis of Variance | 10 | 2008 | 6365 | 0.120 |
Why?
|
| Nephrology | 1 | 2017 | 260 | 0.120 |
Why?
|
| Stress, Physiological | 5 | 2015 | 1402 | 0.120 |
Why?
|
| Meta-Analysis as Topic | 4 | 2008 | 1342 | 0.120 |
Why?
|
| Ventricular Fibrillation | 3 | 2011 | 538 | 0.120 |
Why?
|
| Frail Elderly | 1 | 2018 | 691 | 0.110 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2014 | 176 | 0.110 |
Why?
|
| Regional Blood Flow | 9 | 2007 | 1525 | 0.110 |
Why?
|
| Forecasting | 4 | 2016 | 2948 | 0.110 |
Why?
|
| Confidentiality | 2 | 2017 | 609 | 0.110 |
Why?
|
| Enzyme Inhibitors | 3 | 2023 | 3800 | 0.110 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2015 | 697 | 0.110 |
Why?
|
| Confidence Intervals | 5 | 2012 | 2970 | 0.110 |
Why?
|
| Thromboembolism | 3 | 2015 | 983 | 0.110 |
Why?
|
| Echocardiography, Doppler, Color | 2 | 2012 | 364 | 0.110 |
Why?
|
| Acute Disease | 6 | 2014 | 7141 | 0.110 |
Why?
|
| Fluorobenzenes | 1 | 2014 | 184 | 0.110 |
Why?
|
| Professional Autonomy | 1 | 2014 | 177 | 0.110 |
Why?
|
| Advisory Committees | 1 | 2017 | 773 | 0.110 |
Why?
|
| Organ Size | 15 | 2005 | 2253 | 0.110 |
Why?
|
| Carotid Arteries | 4 | 2007 | 952 | 0.110 |
Why?
|
| Retrospective Studies | 25 | 2023 | 77098 | 0.110 |
Why?
|
| Proline | 5 | 1985 | 458 | 0.110 |
Why?
|
| Benzodiazepines | 1 | 2018 | 1101 | 0.110 |
Why?
|
| Cardiotonic Agents | 3 | 2014 | 535 | 0.110 |
Why?
|
| Geography | 1 | 2014 | 669 | 0.110 |
Why?
|
| Drug Therapy | 1 | 2015 | 497 | 0.100 |
Why?
|
| Government Regulation | 2 | 2020 | 522 | 0.100 |
Why?
|
| Enoxaparin | 2 | 2004 | 377 | 0.100 |
Why?
|
| Propensity Score | 1 | 2018 | 1771 | 0.100 |
Why?
|
| Single-Blind Method | 3 | 2019 | 1589 | 0.100 |
Why?
|
| Fibrinolytic Agents | 4 | 2004 | 2156 | 0.100 |
Why?
|
| Zinc Compounds | 1 | 2011 | 35 | 0.100 |
Why?
|
| Hydroxymethylglutaryl CoA Reductases | 1 | 2011 | 58 | 0.100 |
Why?
|
| Outpatients | 2 | 2021 | 1483 | 0.100 |
Why?
|
| Linear Models | 8 | 2016 | 5948 | 0.100 |
Why?
|
| Arteriosclerosis | 4 | 2011 | 1092 | 0.100 |
Why?
|
| Hyperglycemia | 1 | 2020 | 1368 | 0.100 |
Why?
|
| Survivors | 6 | 2019 | 2286 | 0.100 |
Why?
|
| Growth Differentiation Factor 15 | 2 | 2023 | 176 | 0.100 |
Why?
|
| Random Allocation | 6 | 2018 | 2425 | 0.100 |
Why?
|
| Brazil | 4 | 2017 | 1263 | 0.100 |
Why?
|
| Fibrosis | 4 | 2023 | 2026 | 0.100 |
Why?
|
| Argentina | 3 | 2017 | 232 | 0.090 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 2005 | 371 | 0.090 |
Why?
|
| Manuscripts as Topic | 1 | 2010 | 15 | 0.090 |
Why?
|
| Influenza, Human | 1 | 2022 | 1472 | 0.090 |
Why?
|
| Informed Consent | 1 | 2017 | 991 | 0.090 |
Why?
|
| Odds Ratio | 8 | 2021 | 9846 | 0.090 |
Why?
|
| Vitamins | 2 | 2017 | 1608 | 0.090 |
Why?
|
| Liver Function Tests | 2 | 2009 | 528 | 0.090 |
Why?
|
| Drug Prescriptions | 3 | 2023 | 1636 | 0.090 |
Why?
|
| Regression Analysis | 5 | 2018 | 6452 | 0.090 |
Why?
|
| Diabetic Cardiomyopathies | 1 | 2011 | 96 | 0.090 |
Why?
|
| Probability | 5 | 2008 | 2502 | 0.090 |
Why?
|
| Disease Models, Animal | 13 | 2014 | 18006 | 0.090 |
Why?
|
| Tyrosine | 2 | 2004 | 1460 | 0.090 |
Why?
|
| Death | 3 | 2011 | 675 | 0.090 |
Why?
|
| Exercise Test | 4 | 1998 | 2075 | 0.090 |
Why?
|
| Lovastatin | 1 | 2010 | 120 | 0.090 |
Why?
|
| SRS-A | 3 | 1985 | 156 | 0.090 |
Why?
|
| Investments | 1 | 2011 | 143 | 0.090 |
Why?
|
| Digitalis Glycosides | 1 | 1989 | 47 | 0.090 |
Why?
|
| Logistic Models | 13 | 2016 | 13403 | 0.090 |
Why?
|
| Cell Nucleus | 2 | 1999 | 2968 | 0.090 |
Why?
|
| Alkaline Phosphatase | 2 | 2009 | 865 | 0.090 |
Why?
|
| Coronary Angiography | 6 | 2007 | 4567 | 0.090 |
Why?
|
| Learning Curve | 1 | 2010 | 200 | 0.080 |
Why?
|
| Sample Size | 3 | 2015 | 844 | 0.080 |
Why?
|
| Exercise | 4 | 2020 | 5611 | 0.080 |
Why?
|
| Adult Stem Cells | 1 | 2011 | 216 | 0.080 |
Why?
|
| Probucol | 1 | 2008 | 23 | 0.080 |
Why?
|
| Olfaction Disorders | 1 | 2011 | 222 | 0.080 |
Why?
|
| Life Expectancy | 1 | 2015 | 1183 | 0.080 |
Why?
|
| Pyrazoles | 3 | 2016 | 1970 | 0.080 |
Why?
|
| Receptor, Angiotensin, Type 2 | 3 | 2004 | 67 | 0.080 |
Why?
|
| Erythrocytes | 2 | 2009 | 2452 | 0.080 |
Why?
|
| Aftercare | 3 | 2022 | 860 | 0.080 |
Why?
|
| Acute Lung Injury | 1 | 2012 | 378 | 0.080 |
Why?
|
| Withholding Treatment | 1 | 2013 | 598 | 0.080 |
Why?
|
| Dogs | 4 | 2012 | 3910 | 0.080 |
Why?
|
| Pharmacokinetics | 1 | 1988 | 88 | 0.080 |
Why?
|
| Compliance | 2 | 2005 | 104 | 0.080 |
Why?
|
| Triglycerides | 7 | 2015 | 2450 | 0.080 |
Why?
|
| Neoplasms | 3 | 2012 | 21596 | 0.080 |
Why?
|
| Health Status Disparities | 1 | 2019 | 1794 | 0.080 |
Why?
|
| Health Status | 3 | 2014 | 4030 | 0.080 |
Why?
|
| Clinical Protocols | 3 | 2010 | 1459 | 0.080 |
Why?
|
| Inflammation | 6 | 2024 | 10578 | 0.080 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2011 | 469 | 0.080 |
Why?
|
| Blood Flow Velocity | 7 | 2001 | 1423 | 0.080 |
Why?
|
| Renal Circulation | 3 | 1984 | 333 | 0.080 |
Why?
|
| Glucose | 1 | 2020 | 4391 | 0.080 |
Why?
|
| Prevalence | 11 | 2017 | 15194 | 0.080 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2009 | 430 | 0.080 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2014 | 3328 | 0.070 |
Why?
|
| Chi-Square Distribution | 3 | 2010 | 3510 | 0.070 |
Why?
|
| Tick Infestations | 1 | 2006 | 10 | 0.070 |
Why?
|
| Lipoxins | 1 | 2010 | 411 | 0.070 |
Why?
|
| Germany | 2 | 2006 | 860 | 0.070 |
Why?
|
| Heparin | 2 | 2004 | 1636 | 0.070 |
Why?
|
| Epoetin Alfa | 1 | 2007 | 83 | 0.070 |
Why?
|
| Rickettsia Infections | 1 | 2006 | 9 | 0.070 |
Why?
|
| Cyclic AMP | 4 | 1999 | 1470 | 0.070 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 1998 | 3617 | 0.070 |
Why?
|
| Coronary Care Units | 2 | 2002 | 214 | 0.070 |
Why?
|
| Receptor, Angiotensin, Type 1 | 3 | 2003 | 152 | 0.070 |
Why?
|
| Propranolol | 3 | 1984 | 502 | 0.070 |
Why?
|
| Ixodes | 1 | 2006 | 39 | 0.070 |
Why?
|
| Femoral Artery | 3 | 2007 | 843 | 0.070 |
Why?
|
| Bronchodilator Agents | 1 | 2010 | 502 | 0.070 |
Why?
|
| Pressure | 2 | 2001 | 1203 | 0.070 |
Why?
|
| Drug Approval | 3 | 2017 | 740 | 0.070 |
Why?
|
| Organometallic Compounds | 2 | 2005 | 665 | 0.070 |
Why?
|
| Cyclic AMP Response Element Modulator | 4 | 1999 | 87 | 0.070 |
Why?
|
| Electric Countershock | 1 | 2009 | 535 | 0.070 |
Why?
|
| Capillary Resistance | 1 | 2005 | 5 | 0.070 |
Why?
|
| Simvastatin | 2 | 2009 | 360 | 0.070 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2012 | 964 | 0.070 |
Why?
|
| Life Tables | 2 | 2004 | 370 | 0.070 |
Why?
|
| Ruthenium | 1 | 2005 | 22 | 0.070 |
Why?
|
| Coronary Artery Bypass | 5 | 2009 | 2281 | 0.070 |
Why?
|
| Safety | 5 | 2006 | 1185 | 0.070 |
Why?
|
| Docosahexaenoic Acids | 1 | 2012 | 875 | 0.070 |
Why?
|
| Epinephrine | 3 | 2012 | 793 | 0.070 |
Why?
|
| Matrix Metalloproteinases | 1 | 2008 | 391 | 0.060 |
Why?
|
| Sodium Chloride | 2 | 1985 | 625 | 0.060 |
Why?
|
| Epidemiologic Methods | 4 | 2016 | 1364 | 0.060 |
Why?
|
| Reference Values | 3 | 2012 | 4982 | 0.060 |
Why?
|
| Societies, Medical | 1 | 2017 | 3740 | 0.060 |
Why?
|
| Sweden | 2 | 2005 | 1343 | 0.060 |
Why?
|
| Sex Characteristics | 2 | 2023 | 2585 | 0.060 |
Why?
|
| Antigens, Viral | 2 | 1999 | 1034 | 0.060 |
Why?
|
| Thinness | 1 | 2008 | 479 | 0.060 |
Why?
|
| Age Distribution | 5 | 2009 | 2900 | 0.060 |
Why?
|
| Inflammation Mediators | 2 | 2012 | 1889 | 0.060 |
Why?
|
| Models, Theoretical | 3 | 2012 | 3584 | 0.060 |
Why?
|
| Creatine | 1 | 2006 | 421 | 0.060 |
Why?
|
| Disease Management | 4 | 2015 | 2450 | 0.060 |
Why?
|
| Adenomatous Polyps | 1 | 2005 | 107 | 0.060 |
Why?
|
| Protein Precursors | 3 | 2020 | 1154 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2009 | 35342 | 0.060 |
Why?
|
| Necrosis | 3 | 1998 | 1643 | 0.060 |
Why?
|
| Graft Rejection | 1 | 2017 | 4393 | 0.060 |
Why?
|
| Repressor Proteins | 4 | 1999 | 3020 | 0.060 |
Why?
|
| Chlamydophila pneumoniae | 1 | 2003 | 55 | 0.060 |
Why?
|
| Quinolines | 1 | 2008 | 719 | 0.060 |
Why?
|
| Methoxamine | 4 | 1994 | 45 | 0.060 |
Why?
|
| Scotland | 1 | 2023 | 155 | 0.060 |
Why?
|
| Liver Diseases | 3 | 2009 | 1252 | 0.060 |
Why?
|
| Body Mass Index | 6 | 2009 | 12695 | 0.060 |
Why?
|
| Sulfones | 1 | 2006 | 437 | 0.060 |
Why?
|
| Melatonin | 2 | 1999 | 720 | 0.060 |
Why?
|
| Creatine Kinase | 2 | 2004 | 694 | 0.050 |
Why?
|
| Hyperlipidemias | 2 | 2005 | 786 | 0.050 |
Why?
|
| Mineralocorticoids | 1 | 2022 | 38 | 0.050 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 3 | 2001 | 514 | 0.050 |
Why?
|
| Electrocardiography, Ambulatory | 2 | 2003 | 585 | 0.050 |
Why?
|
| Reproducibility of Results | 7 | 2023 | 19862 | 0.050 |
Why?
|
| Pyrimidines | 1 | 2014 | 2933 | 0.050 |
Why?
|
| Procollagen | 1 | 2023 | 185 | 0.050 |
Why?
|
| Purines | 1 | 2006 | 593 | 0.050 |
Why?
|
| Lipoproteins, LDL | 1 | 2005 | 628 | 0.050 |
Why?
|
| Pentetic Acid | 2 | 1993 | 213 | 0.050 |
Why?
|
| Inpatients | 1 | 2014 | 2495 | 0.050 |
Why?
|
| Drug Synergism | 2 | 2003 | 1791 | 0.050 |
Why?
|
| Azithromycin | 1 | 2003 | 195 | 0.050 |
Why?
|
| RNA, Viral | 3 | 1999 | 2899 | 0.050 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 2 | 2004 | 641 | 0.050 |
Why?
|
| Nitroprusside | 1 | 2002 | 275 | 0.050 |
Why?
|
| Furosemide | 1 | 2022 | 167 | 0.050 |
Why?
|
| Phosphates | 1 | 2005 | 786 | 0.050 |
Why?
|
| Cardiovascular System | 2 | 2020 | 827 | 0.050 |
Why?
|
| Peripheral Arterial Disease | 1 | 2012 | 1184 | 0.050 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2009 | 1130 | 0.050 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2022 | 135 | 0.050 |
Why?
|
| Consensus | 2 | 2023 | 2935 | 0.050 |
Why?
|
| Ectromelia, Infectious | 1 | 2000 | 1 | 0.050 |
Why?
|
| Ectromelia virus | 1 | 2000 | 5 | 0.050 |
Why?
|
| Syndrome | 2 | 2005 | 3248 | 0.050 |
Why?
|
| Receptor, Endothelin A | 1 | 2000 | 58 | 0.050 |
Why?
|
| Radionuclide Ventriculography | 2 | 2000 | 41 | 0.050 |
Why?
|
| Apolipoproteins C | 1 | 2000 | 59 | 0.050 |
Why?
|
| Ventricular Function | 4 | 2005 | 416 | 0.050 |
Why?
|
| Epoprostenol | 1 | 2001 | 254 | 0.050 |
Why?
|
| Cholesterol, VLDL | 1 | 2000 | 65 | 0.050 |
Why?
|
| Lisinopril | 1 | 2000 | 54 | 0.050 |
Why?
|
| Genome-Wide Association Study | 1 | 2020 | 12220 | 0.050 |
Why?
|
| Contractile Proteins | 1 | 2001 | 246 | 0.050 |
Why?
|
| Rodent Diseases | 1 | 2000 | 57 | 0.050 |
Why?
|
| Collagen | 2 | 2002 | 2684 | 0.050 |
Why?
|
| Phenotype | 3 | 2014 | 16331 | 0.050 |
Why?
|
| Phenylbutazone | 1 | 2020 | 8 | 0.050 |
Why?
|
| Tolbutamide | 1 | 2020 | 23 | 0.050 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2021 | 149 | 0.050 |
Why?
|
| Time | 1 | 2002 | 530 | 0.050 |
Why?
|
| Cholesterol Ester Transfer Proteins | 1 | 2021 | 111 | 0.050 |
Why?
|
| Drug Evaluation | 3 | 2004 | 637 | 0.050 |
Why?
|
| Physical Examination | 2 | 2019 | 1239 | 0.050 |
Why?
|
| Antioxidants | 1 | 2008 | 1659 | 0.050 |
Why?
|
| Blotting, Northern | 2 | 1999 | 1581 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 15494 | 0.040 |
Why?
|
| Patient Compliance | 2 | 2005 | 2680 | 0.040 |
Why?
|
| Gene Frequency | 4 | 2008 | 3587 | 0.040 |
Why?
|
| Survival | 1 | 2000 | 162 | 0.040 |
Why?
|
| Guideline Adherence | 1 | 2010 | 2266 | 0.040 |
Why?
|
| Hyperhidrosis | 1 | 2000 | 35 | 0.040 |
Why?
|
| Nutrition Surveys | 2 | 2009 | 1656 | 0.040 |
Why?
|
| Australia | 3 | 2013 | 1167 | 0.040 |
Why?
|
| Health Status Indicators | 1 | 2005 | 968 | 0.040 |
Why?
|
| Sympathetic Nervous System | 3 | 2003 | 514 | 0.040 |
Why?
|
| Encephalomyelitis, Equine | 1 | 1999 | 7 | 0.040 |
Why?
|
| Patient Discharge | 2 | 2022 | 3300 | 0.040 |
Why?
|
| DNA-Binding Proteins | 5 | 2005 | 9639 | 0.040 |
Why?
|
| Stress, Mechanical | 3 | 2010 | 1684 | 0.040 |
Why?
|
| Cerebral Hemorrhage | 2 | 2008 | 2643 | 0.040 |
Why?
|
| Disease-Free Survival | 2 | 2009 | 6891 | 0.040 |
Why?
|
| Drug Contamination | 1 | 2000 | 148 | 0.040 |
Why?
|
| Hypertension, Pulmonary | 3 | 2014 | 1527 | 0.040 |
Why?
|
| Recombinant Proteins | 2 | 2007 | 6608 | 0.040 |
Why?
|
| Health Resources | 1 | 2005 | 911 | 0.040 |
Why?
|
| Apolipoproteins B | 1 | 2000 | 373 | 0.040 |
Why?
|
| Anaerobic Threshold | 1 | 1998 | 52 | 0.040 |
Why?
|
| Feeding Behavior | 1 | 2011 | 3187 | 0.040 |
Why?
|
| Medical Records | 1 | 2004 | 1413 | 0.040 |
Why?
|
| Americas | 1 | 2018 | 111 | 0.040 |
Why?
|
| Liver Cirrhosis | 2 | 1994 | 1864 | 0.040 |
Why?
|
| Oxazoles | 1 | 2020 | 189 | 0.040 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2003 | 790 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2015 | 5522 | 0.040 |
Why?
|
| Blood Pressure Determination | 2 | 2020 | 632 | 0.040 |
Why?
|
| Collagenases | 1 | 1999 | 228 | 0.040 |
Why?
|
| 5' Untranslated Regions | 1 | 1999 | 249 | 0.040 |
Why?
|
| Culture Media | 1 | 2000 | 902 | 0.040 |
Why?
|
| Drug Utilization Review | 1 | 1999 | 245 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2000 | 4414 | 0.040 |
Why?
|
| Combined Modality Therapy | 4 | 2014 | 8621 | 0.040 |
Why?
|
| Photoperiod | 1 | 1998 | 136 | 0.040 |
Why?
|
| Blood Glucose | 3 | 2022 | 6249 | 0.040 |
Why?
|
| Blood | 1 | 2000 | 598 | 0.040 |
Why?
|
| Drug Costs | 3 | 2006 | 1104 | 0.040 |
Why?
|
| Angioedema | 1 | 2019 | 187 | 0.040 |
Why?
|
| Precipitating Factors | 1 | 2017 | 52 | 0.040 |
Why?
|
| Muscular Diseases | 1 | 2002 | 557 | 0.040 |
Why?
|
| Cephradine | 1 | 1977 | 4 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 4 | 2023 | 5385 | 0.040 |
Why?
|
| Prodrugs | 1 | 1999 | 268 | 0.040 |
Why?
|
| Adaptation, Physiological | 2 | 1997 | 1310 | 0.040 |
Why?
|
| Sensitivity and Specificity | 5 | 2015 | 14720 | 0.040 |
Why?
|
| Diphosphonates | 2 | 1993 | 625 | 0.040 |
Why?
|
| Cephalexin | 1 | 1977 | 37 | 0.040 |
Why?
|
| Gadolinium | 2 | 1993 | 951 | 0.040 |
Why?
|
| Angioplasty, Balloon, Coronary | 5 | 2007 | 1873 | 0.040 |
Why?
|
| Graft Survival | 2 | 2018 | 3733 | 0.040 |
Why?
|
| Imidazoles | 1 | 2003 | 1205 | 0.040 |
Why?
|
| Heart Conduction System | 1 | 2003 | 1048 | 0.040 |
Why?
|
| Weight Loss | 1 | 2008 | 2604 | 0.040 |
Why?
|
| Heart Septum | 2 | 2012 | 313 | 0.040 |
Why?
|
| Observer Variation | 3 | 2007 | 2593 | 0.040 |
Why?
|
| Ontario | 1 | 2017 | 381 | 0.040 |
Why?
|
| Glycine | 1 | 2020 | 671 | 0.040 |
Why?
|
| Adrenergic beta-Agonists | 1 | 1998 | 346 | 0.040 |
Why?
|
| Nitric Oxide Synthase | 1 | 1999 | 916 | 0.030 |
Why?
|
| beta 2-Microglobulin | 1 | 2017 | 315 | 0.030 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 1997 | 281 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2001 | 1284 | 0.030 |
Why?
|
| Suprachiasmatic Nucleus | 1 | 1996 | 147 | 0.030 |
Why?
|
| Cystatin C | 1 | 2017 | 250 | 0.030 |
Why?
|
| Colorectal Neoplasms | 2 | 2006 | 6754 | 0.030 |
Why?
|
| Cephalosporins | 1 | 1977 | 203 | 0.030 |
Why?
|
| Dementia | 1 | 2010 | 2501 | 0.030 |
Why?
|
| Antineoplastic Agents | 2 | 2012 | 13655 | 0.030 |
Why?
|
| Adenoma | 1 | 2006 | 2168 | 0.030 |
Why?
|
| Patient Care Management | 1 | 2019 | 306 | 0.030 |
Why?
|
| Endothelin-1 | 2 | 2011 | 313 | 0.030 |
Why?
|
| Obesity | 5 | 2021 | 12705 | 0.030 |
Why?
|
| Physical Exertion | 1 | 1978 | 695 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2010 | 3915 | 0.030 |
Why?
|
| Insurance | 1 | 2017 | 111 | 0.030 |
Why?
|
| Adolescent | 7 | 2022 | 85649 | 0.030 |
Why?
|
| Self Efficacy | 1 | 2019 | 610 | 0.030 |
Why?
|
| Piperazines | 1 | 2006 | 2488 | 0.030 |
Why?
|
| Drug Interactions | 2 | 2010 | 1458 | 0.030 |
Why?
|
| Longitudinal Studies | 3 | 2018 | 13921 | 0.030 |
Why?
|
| Periodicity | 1 | 1996 | 363 | 0.030 |
Why?
|
| Life Style | 3 | 2015 | 3824 | 0.030 |
Why?
|
| Ferritins | 1 | 2017 | 590 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2005 | 2948 | 0.030 |
Why?
|
| Apolipoproteins E | 1 | 2000 | 1438 | 0.030 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 1998 | 476 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2006 | 3081 | 0.030 |
Why?
|
| Radiography | 2 | 1999 | 7010 | 0.030 |
Why?
|
| Bradykinin | 1 | 1995 | 214 | 0.030 |
Why?
|
| Injections, Subcutaneous | 2 | 2010 | 664 | 0.030 |
Why?
|
| China | 1 | 2020 | 2246 | 0.030 |
Why?
|
| Administration, Oral | 3 | 2015 | 3913 | 0.030 |
Why?
|
| Databases, Factual | 3 | 2017 | 7716 | 0.030 |
Why?
|
| Stochastic Processes | 1 | 2015 | 344 | 0.030 |
Why?
|
| Dopamine | 1 | 2001 | 1589 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 1998 | 1950 | 0.030 |
Why?
|
| Homocysteine | 2 | 2008 | 647 | 0.030 |
Why?
|
| Young Adult | 4 | 2014 | 56350 | 0.030 |
Why?
|
| Telemetry | 1 | 1995 | 205 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2000 | 8297 | 0.030 |
Why?
|
| Hydrochlorothiazide | 1 | 2014 | 98 | 0.030 |
Why?
|
| Resuscitation | 2 | 2011 | 657 | 0.030 |
Why?
|
| South Africa | 2 | 2013 | 1728 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2002 | 1167 | 0.030 |
Why?
|
| ROC Curve | 2 | 2012 | 3528 | 0.030 |
Why?
|
| Antithrombins | 1 | 2016 | 304 | 0.030 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2014 | 101 | 0.030 |
Why?
|
| Physicians, Primary Care | 1 | 2020 | 577 | 0.030 |
Why?
|
| Sodium Channel Blockers | 1 | 2014 | 176 | 0.030 |
Why?
|
| USSR | 1 | 2012 | 21 | 0.030 |
Why?
|
| Oxygen Consumption | 2 | 1998 | 1869 | 0.030 |
Why?
|
| Computer Simulation | 2 | 2018 | 6191 | 0.030 |
Why?
|
| Ischemic Attack, Transient | 2 | 2015 | 934 | 0.030 |
Why?
|
| Tomography, Emission-Computed | 1 | 1996 | 1144 | 0.030 |
Why?
|
| Timolol | 3 | 1978 | 52 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2014 | 425 | 0.030 |
Why?
|
| Blood-Air Barrier | 1 | 2012 | 25 | 0.030 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2015 | 334 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2005 | 3391 | 0.030 |
Why?
|
| Animals, Newborn | 1 | 1998 | 2723 | 0.030 |
Why?
|
| Depression | 3 | 2020 | 7733 | 0.030 |
Why?
|
| Gadolinium DTPA | 2 | 1993 | 836 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2020 | 3001 | 0.030 |
Why?
|
| Cell Membrane | 2 | 1999 | 3744 | 0.030 |
Why?
|
| Receptors, Formyl Peptide | 1 | 2012 | 145 | 0.030 |
Why?
|
| Gene Deletion | 2 | 2001 | 2751 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2006 | 3839 | 0.030 |
Why?
|
| Hypertrophy | 1 | 2013 | 568 | 0.030 |
Why?
|
| Adrenomedullin | 1 | 2011 | 87 | 0.030 |
Why?
|
| Pyridones | 1 | 2016 | 712 | 0.030 |
Why?
|
| Mass Screening | 3 | 2009 | 5238 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 1999 | 4751 | 0.020 |
Why?
|
| Wound Healing | 1 | 2002 | 2781 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2004 | 3957 | 0.020 |
Why?
|
| Health Surveys | 1 | 2001 | 4030 | 0.020 |
Why?
|
| Airway Resistance | 1 | 2012 | 404 | 0.020 |
Why?
|
| Ligands | 1 | 1998 | 3293 | 0.020 |
Why?
|
| Netherlands | 1 | 2016 | 2170 | 0.020 |
Why?
|
| Gene Expression Regulation | 3 | 1999 | 12071 | 0.020 |
Why?
|
| Transcription Factor RelA | 1 | 2012 | 275 | 0.020 |
Why?
|
| Alleles | 3 | 2001 | 6931 | 0.020 |
Why?
|
| Propylamines | 1 | 1991 | 165 | 0.020 |
Why?
|
| Myocarditis | 1 | 1998 | 770 | 0.020 |
Why?
|
| Hospital Mortality | 3 | 2014 | 5310 | 0.020 |
Why?
|
| Tissue Plasminogen Activator | 1 | 1997 | 1262 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 4 | 2006 | 6171 | 0.020 |
Why?
|
| Blood Urea Nitrogen | 1 | 2010 | 191 | 0.020 |
Why?
|
| Analog-Digital Conversion | 1 | 2010 | 23 | 0.020 |
Why?
|
| Video Recording | 2 | 2010 | 944 | 0.020 |
Why?
|
| Body Weight | 9 | 1985 | 4664 | 0.020 |
Why?
|
| Glycopeptides | 1 | 2011 | 224 | 0.020 |
Why?
|
| New York | 1 | 2013 | 886 | 0.020 |
Why?
|
| Patient Dropouts | 1 | 2012 | 421 | 0.020 |
Why?
|
| 8,11,14-Eicosatrienoic Acid | 1 | 2010 | 62 | 0.020 |
Why?
|
| Kinetics | 4 | 1996 | 6474 | 0.020 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2018 | 974 | 0.020 |
Why?
|
| Macrophages, Alveolar | 1 | 2012 | 407 | 0.020 |
Why?
|
| Heart Transplantation | 1 | 2003 | 3119 | 0.020 |
Why?
|
| Base Sequence | 5 | 1999 | 12797 | 0.020 |
Why?
|
| Mice | 6 | 2012 | 81045 | 0.020 |
Why?
|
| Hospital Costs | 2 | 2006 | 980 | 0.020 |
Why?
|
| Selection Bias | 1 | 1991 | 369 | 0.020 |
Why?
|
| Thiazoles | 1 | 2016 | 1484 | 0.020 |
Why?
|
| Quality-Adjusted Life Years | 1 | 1995 | 1679 | 0.020 |
Why?
|
| Contrast Media | 2 | 1993 | 5295 | 0.020 |
Why?
|
| Cineangiography | 1 | 1988 | 124 | 0.020 |
Why?
|
| Conflict of Interest | 1 | 2014 | 542 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 1991 | 1372 | 0.020 |
Why?
|
| Patient Admission | 2 | 2009 | 1380 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2001 | 4465 | 0.020 |
Why?
|
| Numerical Analysis, Computer-Assisted | 1 | 2008 | 125 | 0.020 |
Why?
|
| Neutrophils | 2 | 2012 | 3711 | 0.020 |
Why?
|
| Algorithms | 4 | 2006 | 13853 | 0.020 |
Why?
|
| Amiodarone | 1 | 2010 | 212 | 0.020 |
Why?
|
| Ranitidine | 1 | 1988 | 34 | 0.020 |
Why?
|
| Patient Care Team | 1 | 1999 | 2527 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 1999 | 1086 | 0.020 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 1994 | 1504 | 0.020 |
Why?
|
| Delayed-Action Preparations | 2 | 2003 | 965 | 0.020 |
Why?
|
| Synaptic Transmission | 1 | 1994 | 1179 | 0.020 |
Why?
|
| Molecular Sequence Data | 5 | 1999 | 18112 | 0.020 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 1987 | 65 | 0.020 |
Why?
|
| Aspartate Aminotransferases | 1 | 2009 | 418 | 0.020 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2018 | 1527 | 0.020 |
Why?
|
| Hospitals | 1 | 2021 | 3937 | 0.020 |
Why?
|
| Dilatation | 1 | 1988 | 286 | 0.020 |
Why?
|
| Rickettsia | 1 | 2006 | 10 | 0.020 |
Why?
|
| Cytokines | 1 | 2002 | 7317 | 0.020 |
Why?
|
| Bilirubin | 1 | 2009 | 424 | 0.020 |
Why?
|
| International Cooperation | 1 | 2013 | 1421 | 0.020 |
Why?
|
| Cell Size | 1 | 2009 | 643 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2020 | 3439 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2011 | 1653 | 0.020 |
Why?
|
| Vitamin K | 1 | 2009 | 294 | 0.020 |
Why?
|
| Organ Culture Techniques | 2 | 1999 | 808 | 0.020 |
Why?
|
| Heart Aneurysm | 1 | 1987 | 120 | 0.020 |
Why?
|
| Half-Life | 1 | 1987 | 658 | 0.020 |
Why?
|
| Urticaria | 1 | 1988 | 150 | 0.020 |
Why?
|
| Galactose | 1 | 1987 | 306 | 0.020 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2007 | 233 | 0.020 |
Why?
|
| Smoking Cessation | 2 | 2010 | 2068 | 0.020 |
Why?
|
| Alanine Transaminase | 1 | 2009 | 592 | 0.020 |
Why?
|
| Shock, Septic | 1 | 2013 | 773 | 0.020 |
Why?
|
| Hematologic Agents | 1 | 2006 | 39 | 0.020 |
Why?
|
| Population Density | 1 | 2006 | 194 | 0.020 |
Why?
|
| Protein Binding | 1 | 1998 | 9387 | 0.020 |
Why?
|
| Drug Utilization | 1 | 1992 | 1181 | 0.020 |
Why?
|
| Motion | 1 | 2010 | 797 | 0.020 |
Why?
|
| Diet | 1 | 1984 | 7923 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2000 | 3014 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 2885 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2009 | 674 | 0.020 |
Why?
|
| Ligation | 3 | 1999 | 453 | 0.020 |
Why?
|
| Embolism | 1 | 2009 | 409 | 0.020 |
Why?
|
| Annexin A5 | 1 | 2005 | 103 | 0.020 |
Why?
|
| Thiazolidinediones | 1 | 2008 | 476 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2021 | 4551 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2003 | 7153 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2007 | 475 | 0.020 |
Why?
|
| Nadolol | 1 | 1984 | 30 | 0.020 |
Why?
|
| Mitomycins | 1 | 1984 | 47 | 0.020 |
Why?
|
| Larva | 1 | 2006 | 517 | 0.020 |
Why?
|
| Telomere | 1 | 2011 | 909 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 1999 | 2837 | 0.020 |
Why?
|
| Endothelium, Vascular | 2 | 1995 | 4455 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2005 | 459 | 0.020 |
Why?
|
| Sequence Alignment | 2 | 1999 | 2257 | 0.020 |
Why?
|
| International Normalized Ratio | 1 | 2006 | 365 | 0.020 |
Why?
|
| Chlorothiazide | 2 | 1975 | 7 | 0.020 |
Why?
|
| Brain Infarction | 1 | 2006 | 296 | 0.020 |
Why?
|
| Lung | 1 | 2023 | 9826 | 0.020 |
Why?
|
| G1 Phase | 1 | 2005 | 415 | 0.010 |
Why?
|
| Dialysis | 1 | 2003 | 75 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 2012 | 1737 | 0.010 |
Why?
|
| Leukocytes | 1 | 2012 | 2039 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2017 | 4147 | 0.010 |
Why?
|
| Chlamydophila Infections | 1 | 2003 | 23 | 0.010 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2003 | 79 | 0.010 |
Why?
|
| Asia, Southeastern | 1 | 2003 | 111 | 0.010 |
Why?
|
| Patient Readmission | 1 | 2017 | 3111 | 0.010 |
Why?
|
| Homeostasis | 1 | 2014 | 3335 | 0.010 |
Why?
|
| Reference Standards | 1 | 2007 | 1020 | 0.010 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2007 | 430 | 0.010 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 2723 | 0.010 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2005 | 731 | 0.010 |
Why?
|
| Amino Acid Sequence | 3 | 1999 | 13814 | 0.010 |
Why?
|
| Atenolol | 1 | 2003 | 100 | 0.010 |
Why?
|
| Fluoroquinolones | 1 | 2005 | 308 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2005 | 595 | 0.010 |
Why?
|
| Brain Mapping | 1 | 1998 | 6669 | 0.010 |
Why?
|
| Attitude to Health | 1 | 1991 | 2051 | 0.010 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2006 | 341 | 0.010 |
Why?
|
| Phylogeny | 2 | 1999 | 2797 | 0.010 |
Why?
|
| Thoracic Surgery | 2 | 1986 | 713 | 0.010 |
Why?
|
| Benzhydryl Compounds | 1 | 1988 | 840 | 0.010 |
Why?
|
| Activating Transcription Factor 2 | 1 | 2001 | 45 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2012 | 2915 | 0.010 |
Why?
|
| Blood Platelets | 1 | 2012 | 2506 | 0.010 |
Why?
|
| Length of Stay | 2 | 2005 | 6294 | 0.010 |
Why?
|
| DNA, Bacterial | 1 | 2006 | 1465 | 0.010 |
Why?
|
| New Zealand | 1 | 2002 | 357 | 0.010 |
Why?
|
| Sodium | 3 | 1983 | 1627 | 0.010 |
Why?
|
| Molecular Structure | 1 | 2005 | 1907 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2005 | 1097 | 0.010 |
Why?
|
| Body Height | 1 | 2007 | 1574 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2001 | 286 | 0.010 |
Why?
|
| Rehabilitation | 1 | 2001 | 134 | 0.010 |
Why?
|
| Central Venous Pressure | 2 | 1977 | 78 | 0.010 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1984 | 692 | 0.010 |
Why?
|
| Body Constitution | 1 | 2000 | 278 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2005 | 2295 | 0.010 |
Why?
|
| Cells, Cultured | 2 | 2011 | 19223 | 0.010 |
Why?
|
| Anti-Inflammatory Agents | 1 | 1990 | 1788 | 0.010 |
Why?
|
| Equidae | 1 | 1999 | 10 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2005 | 1758 | 0.010 |
Why?
|
| Cough | 1 | 2003 | 555 | 0.010 |
Why?
|
| Decision Making | 1 | 2014 | 3869 | 0.010 |
Why?
|
| Preventive Medicine | 1 | 2001 | 263 | 0.010 |
Why?
|
| Transcription Factor AP-1 | 1 | 2001 | 317 | 0.010 |
Why?
|
| Vasoconstriction | 2 | 1994 | 596 | 0.010 |
Why?
|
| Warfarin | 1 | 2008 | 1493 | 0.010 |
Why?
|
| Central America | 1 | 1999 | 68 | 0.010 |
Why?
|
| Cisplatin | 1 | 2005 | 1637 | 0.010 |
Why?
|
| Apolipoprotein C-III | 1 | 2000 | 202 | 0.010 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2001 | 452 | 0.010 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 1 | 1999 | 48 | 0.010 |
Why?
|
| Biopsy | 1 | 2011 | 6756 | 0.010 |
Why?
|
| Signal Transduction | 2 | 1999 | 23387 | 0.010 |
Why?
|
| Phosphorylation | 2 | 2001 | 8436 | 0.010 |
Why?
|
| Genetic Variation | 2 | 2008 | 6540 | 0.010 |
Why?
|
| Horses | 1 | 1999 | 304 | 0.010 |
Why?
|
| Dyslipidemias | 1 | 2006 | 848 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 1999 | 829 | 0.010 |
Why?
|
| Finite Element Analysis | 1 | 2001 | 431 | 0.010 |
Why?
|
| Serum Amyloid A Protein | 1 | 1998 | 121 | 0.010 |
Why?
|
| Second Messenger Systems | 1 | 1999 | 206 | 0.010 |
Why?
|
| Cell Division | 1 | 2005 | 4564 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 1999 | 534 | 0.010 |
Why?
|
| Inbreeding | 1 | 1977 | 49 | 0.010 |
Why?
|
| Lipid Metabolism | 1 | 2006 | 1887 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 1999 | 964 | 0.010 |
Why?
|
| Cats | 1 | 1999 | 998 | 0.010 |
Why?
|
| Antibodies, Bacterial | 1 | 2003 | 1469 | 0.010 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 1984 | 798 | 0.010 |
Why?
|
| Hydralazine | 1 | 1996 | 38 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1983 | 3133 | 0.010 |
Why?
|
| Cross-Sectional Studies | 2 | 2008 | 24913 | 0.010 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 1 | 1999 | 202 | 0.010 |
Why?
|
| American Heart Association | 1 | 2001 | 1055 | 0.010 |
Why?
|
| Drinking Behavior | 1 | 1977 | 103 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2001 | 1727 | 0.010 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 1999 | 491 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2000 | 2085 | 0.010 |
Why?
|
| Terminology as Topic | 1 | 2003 | 1548 | 0.010 |
Why?
|
| Apolipoproteins | 1 | 1998 | 315 | 0.010 |
Why?
|
| Biological Availability | 1 | 1977 | 396 | 0.010 |
Why?
|
| Capsid | 1 | 1998 | 436 | 0.010 |
Why?
|
| Conserved Sequence | 1 | 1999 | 1202 | 0.010 |
Why?
|
| Trimethaphan | 1 | 1975 | 13 | 0.010 |
Why?
|
| Motor Activity | 1 | 2006 | 2714 | 0.010 |
Why?
|
| Phenoxybenzamine | 1 | 1975 | 54 | 0.010 |
Why?
|
| Genome, Viral | 1 | 1999 | 667 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 1999 | 1799 | 0.010 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 1999 | 638 | 0.010 |
Why?
|
| Cell Line | 1 | 2010 | 15994 | 0.010 |
Why?
|
| Value of Life | 1 | 1995 | 97 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2002 | 2633 | 0.010 |
Why?
|
| Growth | 1 | 1977 | 376 | 0.010 |
Why?
|
| Diuresis | 1 | 1975 | 116 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1998 | 2049 | 0.010 |
Why?
|
| Species Specificity | 1 | 1999 | 2479 | 0.010 |
Why?
|
| Methods | 2 | 1972 | 1128 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2005 | 2842 | 0.010 |
Why?
|
| Consciousness | 2 | 1995 | 571 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2011 | 10472 | 0.010 |
Why?
|
| Viral Envelope Proteins | 1 | 1998 | 635 | 0.010 |
Why?
|
| Atropine | 1 | 1975 | 244 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2001 | 3701 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2005 | 5975 | 0.010 |
Why?
|
| Physical Conditioning, Animal | 1 | 1978 | 362 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2002 | 20774 | 0.010 |
Why?
|
| Glucose Intolerance | 1 | 1998 | 577 | 0.010 |
Why?
|
| DNA Primers | 1 | 1999 | 2892 | 0.010 |
Why?
|
| Health Behavior | 1 | 2006 | 2630 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2005 | 2706 | 0.010 |
Why?
|
| Spleen | 1 | 2000 | 2359 | 0.010 |
Why?
|
| Water-Electrolyte Balance | 1 | 1975 | 346 | 0.010 |
Why?
|
| Rheology | 1 | 1994 | 345 | 0.010 |
Why?
|
| Fourier Analysis | 1 | 1994 | 447 | 0.010 |
Why?
|
| Electromagnetic Phenomena | 1 | 1994 | 161 | 0.010 |
Why?
|
| DNA, Viral | 1 | 2000 | 2224 | 0.010 |
Why?
|
| Carbamates | 1 | 1975 | 195 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2011 | 11470 | 0.010 |
Why?
|
| Growth Hormone | 1 | 1996 | 703 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2005 | 4554 | 0.010 |
Why?
|
| Viral Vaccines | 1 | 1999 | 636 | 0.010 |
Why?
|
| Body Surface Area | 1 | 1973 | 198 | 0.010 |
Why?
|
| Urethane | 1 | 1972 | 40 | 0.010 |
Why?
|
| Digitalis | 1 | 1992 | 14 | 0.010 |
Why?
|
| Rats, Mutant Strains | 2 | 1982 | 70 | 0.010 |
Why?
|
| Plants, Toxic | 1 | 1992 | 76 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2000 | 6313 | 0.010 |
Why?
|
| Ouabain | 1 | 1972 | 264 | 0.010 |
Why?
|
| Brain | 1 | 1999 | 26343 | 0.010 |
Why?
|
| Diltiazem | 1 | 1992 | 133 | 0.010 |
Why?
|
| Viral Proteins | 1 | 1999 | 1899 | 0.010 |
Why?
|
| Pentobarbital | 1 | 1972 | 155 | 0.010 |
Why?
|
| Markov Chains | 1 | 1995 | 969 | 0.010 |
Why?
|
| Health Care Costs | 1 | 2005 | 3203 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 11363 | 0.010 |
Why?
|
| Plants, Medicinal | 1 | 1992 | 167 | 0.010 |
Why?
|
| Tail | 1 | 1971 | 97 | 0.010 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 1984 | 2229 | 0.010 |
Why?
|
| Vena Cava, Superior | 1 | 1972 | 194 | 0.010 |
Why?
|
| Cytoplasmic Granules | 1 | 1974 | 610 | 0.010 |
Why?
|
| DNA Transposable Elements | 1 | 1995 | 748 | 0.010 |
Why?
|
| Anti-Anxiety Agents | 1 | 1994 | 390 | 0.010 |
Why?
|
| Remission Induction | 1 | 1996 | 2384 | 0.010 |
Why?
|
| Naloxone | 1 | 1973 | 367 | 0.010 |
Why?
|
| Transfection | 1 | 1999 | 5892 | 0.010 |
Why?
|
| Hospitals, Teaching | 1 | 1995 | 1179 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2005 | 5851 | 0.010 |
Why?
|
| Genetic Linkage | 1 | 1996 | 2422 | 0.010 |
Why?
|
| Water | 1 | 1996 | 1388 | 0.010 |
Why?
|
| Calcium | 2 | 1999 | 5753 | 0.010 |
Why?
|
| Light | 1 | 1996 | 1374 | 0.010 |
Why?
|
| Endothelins | 1 | 1990 | 138 | 0.010 |
Why?
|
| Postmenopause | 1 | 1998 | 2461 | 0.010 |
Why?
|
| Apoptosis | 1 | 2005 | 9715 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2005 | 16665 | 0.010 |
Why?
|
| Hematocrit | 2 | 1984 | 636 | 0.010 |
Why?
|
| Terfenadine | 1 | 1988 | 15 | 0.010 |
Why?
|
| Succinylcholine | 1 | 1988 | 66 | 0.000 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 1995 | 1538 | 0.000 |
Why?
|
| Sequence Analysis, DNA | 1 | 1999 | 4801 | 0.000 |
Why?
|
| Radioimmunoassay | 1 | 1988 | 918 | 0.000 |
Why?
|
| Allylamine | 1 | 1986 | 10 | 0.000 |
Why?
|
| Kidney Cortex | 1 | 1987 | 186 | 0.000 |
Why?
|
| Rats, Inbred WKY | 1 | 1986 | 158 | 0.000 |
Why?
|
| Liver | 2 | 2000 | 7470 | 0.000 |
Why?
|
| Histamine | 1 | 1988 | 507 | 0.000 |
Why?
|
| Denervation | 1 | 1987 | 278 | 0.000 |
Why?
|
| Depression, Chemical | 1 | 1985 | 191 | 0.000 |
Why?
|
| Decision Support Techniques | 1 | 1995 | 1952 | 0.000 |
Why?
|
| Rabbits | 1 | 1991 | 4886 | 0.000 |
Why?
|
| Sister Chromatid Exchange | 1 | 1984 | 60 | 0.000 |
Why?
|
| Erythrocyte Volume | 1 | 1984 | 30 | 0.000 |
Why?
|
| Transcription, Genetic | 1 | 1999 | 7721 | 0.000 |
Why?
|
| Macrophages | 1 | 1999 | 5655 | 0.000 |
Why?
|
| Infusions, Parenteral | 1 | 1984 | 415 | 0.000 |
Why?
|
| Mitomycin | 1 | 1984 | 259 | 0.000 |
Why?
|
| Kidney Tubules | 1 | 1984 | 486 | 0.000 |
Why?
|
| Boston | 1 | 1995 | 9305 | 0.000 |
Why?
|
| Microcirculation | 1 | 1987 | 1285 | 0.000 |
Why?
|
| Remission, Spontaneous | 1 | 1983 | 380 | 0.000 |
Why?
|
| Activities of Daily Living | 1 | 1991 | 2414 | 0.000 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1993 | 8300 | 0.000 |
Why?
|
| Kidney Glomerulus | 1 | 1984 | 697 | 0.000 |
Why?
|
| Transcription Factors | 1 | 2001 | 12164 | 0.000 |
Why?
|
| Chlorides | 2 | 1975 | 667 | 0.000 |
Why?
|
| Perfusion | 1 | 1985 | 1359 | 0.000 |
Why?
|
| Capillary Permeability | 1 | 1984 | 798 | 0.000 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1997 | 8925 | 0.000 |
Why?
|
| Papillary Muscles | 1 | 1980 | 200 | 0.000 |
Why?
|
| Longevity | 1 | 1987 | 1069 | 0.000 |
Why?
|
| Blood Proteins | 2 | 1975 | 1122 | 0.000 |
Why?
|
| Pregnancy | 2 | 1978 | 29087 | 0.000 |
Why?
|
| Particle Size | 1 | 1982 | 1640 | 0.000 |
Why?
|
| Long-Term Care | 1 | 1982 | 607 | 0.000 |
Why?
|
| Quality of Health Care | 1 | 1993 | 4369 | 0.000 |
Why?
|
| Child, Preschool | 1 | 2000 | 40955 | 0.000 |
Why?
|
| Drinking | 1 | 1978 | 197 | 0.000 |
Why?
|
| Maternal-Fetal Exchange | 1 | 1978 | 455 | 0.000 |
Why?
|
| Microspheres | 1 | 1978 | 777 | 0.000 |
Why?
|
| Skin | 1 | 1988 | 4353 | 0.000 |
Why?
|
| Bone Marrow | 1 | 1984 | 2941 | 0.000 |
Why?
|
| Chromatography, Gas | 1 | 1973 | 156 | 0.000 |
Why?
|
| Kidney Medulla | 1 | 1974 | 182 | 0.000 |
Why?
|
| Venous Pressure | 1 | 1972 | 56 | 0.000 |
Why?
|
| Ureter | 1 | 1975 | 374 | 0.000 |
Why?
|
| Mathematics | 1 | 1973 | 727 | 0.000 |
Why?
|
| Plethysmography | 1 | 1972 | 180 | 0.000 |
Why?
|
| Vena Cava, Inferior | 1 | 1975 | 436 | 0.000 |
Why?
|
| Coronary Circulation | 1 | 1978 | 1572 | 0.000 |
Why?
|
| Blood Circulation | 1 | 1972 | 251 | 0.000 |
Why?
|
| Injections, Intravenous | 1 | 1973 | 1420 | 0.000 |
Why?
|
| Microscopy, Electron | 1 | 1974 | 2645 | 0.000 |
Why?
|
| DNA | 1 | 1984 | 7289 | 0.000 |
Why?
|
| Portal Vein | 1 | 1972 | 437 | 0.000 |
Why?
|
| Catheterization | 1 | 1972 | 1468 | 0.000 |
Why?
|
| Pulmonary Artery | 1 | 1972 | 1911 | 0.000 |
Why?
|
| Intestinal Mucosa | 1 | 1973 | 3038 | 0.000 |
Why?
|